GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development workPUBT·Aug 6 at 06:26 AMGHRS+2.44%
GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001PUBT·Aug 6 at 06:19 AMGHRS+2.44%
Macro Crosscurrents Shape Divergent Paths for 10 Off-the-Radar EquitiesGlobal Report·Aug 4 at 04:17 AMGHRS+2.44%BEP+2.26%
Is GH Research (GHRS) Fully Valued Following Its Share Price Surge?Simplywall·Aug 1 at 02:22 PMGHRS+2.44%
Global capital pivots to idiosyncratic U.S. assets as macro headwinds intensifyGlobal Report·Jul 24 at 04:13 AMNPT0.00%NG+3.69%
Q1 2026 Overhauls: Strategic Pivots Across Retail, Energy, and Niche TechGlobal Report·Jul 22 at 04:18 AMSIGA+2.89%ADUR+2.49%
Capital in the Crevices: What the Market's Long Tail Tells Us About 2026Global Report·Jul 19 at 04:13 AMENVX+1.10%DLB-0.74%
Tech and Biotech Sectors See Specialized Consolidation Amid 2026 Regulatory MilestonesGlobal Report·Jul 18 at 04:12 AMUCAR-0.96%BETA-3.86%
Why Is GH Research Stock Trading Higher on Thursday?benzinga_article·Jul 16 at 11:36 AMGHRS+2.44%ATAI+0.27%
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions | LLY Stock NewsStockTitan·Jul 15 at 09:45 PMLLY+0.83%ATAI+0.27%
